Abstract :Despite the recent advances in medical and surgical therapies, the treatment of chronic osteomyelitis (bone and joint infection), especially the treatment of methicillin-resistant Staphylococcus aureus (MRSA) osteomyelitis, still remains challenging and is associated with high recurrence rate, morbidity and substantial healthcare cost [1,2]. Current treatment of chronic osteomyelitis primarily involves the surgical debridement of diseased bone tissue followed by long term systematic antibiotic therapy. Poly(methyl methacrylate) (PMMA) beads impregnated with vancomycin, gentamicin or tobramycin have been used commonly for many years as main stream local delivery vehicle in osteomyelitis treatment [3]. However, PMMA beads cannot be degraded or absorbed in the body and it must be removed in a second operation along with its suboptimal release profile with meager 25-50% of the antibiotic can be eluted in 4 weeks time, which is far away from being a controlled antibiotic drug delivery carrier [4].